TR-002

Phase 1Small molecule

UUniversity of California, Davis

TR-002 is one of 36 small molecule programs targeting Advanced Malignant Solid Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid NeoplasmRecruiting

Advanced Malignant Solid NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

37 competitors in Advanced Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Phase 3

2 2

Lynparza

AstraZeneca

Phase 2

6 3

Ibrance

Pfizer

Phase 2

4 4

Taxol

Teva

Phase 2

2 5

Balversa

Johnson & Johnson

Phase 2

2 6

Koselugo

AstraZeneca

Phase 2

2 7

Retevmo

Eli Lilly

Phase 2

1 8

Herceptin

Roche

Phase 2

1 9

Keytruda

Merck & Co.

Phase 2

1 10

Vitrakvi

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Recruiting

Advanced Malignant Solid Neoplasm

NCT07189195

Clinical

Trials by Indication[1]

Advanced Malignant Solid Neoplasm1 trial

A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors

Recruiting·UUniversity of California, Davis·Phase 1·NCT07189195·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TR-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TR-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TR-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Davis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, Davis

TR-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Advanced Malignant Solid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News